2′-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1271-1276

  Weitzman, Sheila ^a   Braier, Jorge ^b   Donadieu, Jean ^c   Egeler, R Maarten ^d   Grois, Nicole ^e   Ladisch, Stephan ^f   Pötschger, Ulrike ^e   Webb, David ^g   Whitlock, James ^h   Arceci, Robert J ⁱ  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Division of Oncology   (Austria)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

2 CdA; Cladribine; LCH; Salvage therapy

Indexed keywords

CLADRIBINE; 2 CHLOROADENOSINE; 2' CHLORO 2' DEOXYADENOSINE; 2'-CHLORO-2'-DEOXYADENOSINE; ANTIMETABOLITE; DEOXYADENOSINE DERIVATIVE; DRUG DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG EFFICACY; HISTIOCYTOSIS X; HUMAN; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL RATE; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HISTIOCYTE; INFANT; KAPLAN MEIER METHOD; MALE; MULTICENTER STUDY; NEWBORN; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

2-CHLOROADENOSINE; ANTIMETABOLITES; DEOXYADENOSINES; FEMALE; HISTIOCYTES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; PROSPECTIVE STUDIES; RISK; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 70449727017     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22229     Document Type: Article

References (30)

1. Van den Neste E, Cardoen S, Offner F, et al. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: Fludarabine and cladribine (review). Int J Oncol 2005;27:1113-1124.
2. Santana VM, Mirro JJ, Kearns C, et al. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992;10:364-370.
3. Saven A, Lemon RH, Kosty M, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570-574.
4. Saven A, Foon K, Piro L. 2-chlorodeoxyadenosine induced complete remissions in Langerhans Cell Histiocytosis. Ann Intern Med 1994;21:430-432.
5. Weitzman S, Wayne AS, Arceci R, et al. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the Histiocyte Society and review of the literature. Med Pediatr Oncol 1999;33:476-481.
6. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral adminstration in leukemia patients. Clin Cancer Res 1995;1:385-390.
7. Larson RA, Mick R, Speilberger RT, et al. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol 1996;14:188-195.
8. Dann EJ, Anastasi J, Larson RA. High dose Cladribine therapy for chronic myelogenous leukemia in the accelerated blast phase. J Clin Oncol 1998;16:1498-1504.
9. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-444.
10. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. Klin Padiatr 2000;212:139-144.
11. Ladisch S, Gadner H, Aricó M, et al. A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23:107-110.
12. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001;138:728-734.
13. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans Cell Histiocytosis: An important prognostic indicator. Med Pediatr Oncol 2002;39:581-585.
14. Anon. A multicentre retrospective survey of LCH: 348 cases observed between 1983 and 1993. The French LCH Study Group. Arch Dis Child 1996;75:17-24.
15. Dimopoulos MA, Theodorakis M, Kostis E, et al. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. Leuk Lymphoma 1996;25:187-189.
16. Saven A, Burian C. Cladribine activity in adult Langerhans cell histiocytosis. Blood 1999;93:4125-4130.
17. Goh NS, McDonald CE, Macgregor DP, et al. Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Respirology 2003;8:91-94.
18. Stine KC, Saylors RL, Willimas LL, et al. 2-chorodeoxyadenosine (2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 1997;29:288-292.
19. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002;3:244-250.
20. Grau J, Ribera JM, Tormo M, et al. Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients. Med Clin 2001;116:339-342.
21. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001;19:2804-2811.
22. Rodriguez-Galindo C, Kelly P, Jeng M, et al. Treatment of children wth Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Am J Hematol 2002;69:179-184.
23. Niesvizky R, Zhu AX, Louie D, et al. Epstein-Barr-virus-associated lymphoma after treatment of macroglobulinemia with cladribine. N Engl J Med 1999;341:55-56.
24. Goodman GR, Burian C, Koziol JA, et al. Extended follow up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-896.
25. Kurzrock R, Stromm SS, Estey E, et al. Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 1997;15:1803 (abstract).
26. Au WY, Klasa RJ, Gallagher R, et al. Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience. Blood 1998;92:1160 (abstract).
27. Cheson B, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemia. J Clin Oncol 1999;13:2454-2464.
28. Tetreault SA, Saven A. Delayed onset of autoimune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia. Leuk Lymphoma 2000;37:125-130.
29. Grey MR, Flanagan NG, Kelsey PR. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukemia. Clin Lab Haematol 2000;22:111-113.
30. Bernard F, Thomas C, Bertrand Y, et al. Multicentre pilot study of 2-chlorodeoxyadenosine and cytosine -arabinoside combined chemotherapy in refractory Langerhans Cell histiocytosis with haematological dysfunction. Eur J Cancer 2005;41:2682-2689.